KDMN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KDMN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Kadmon Holdings's share price is $9.50. Kadmon Holdings's Tangible Book per Share of Sep. 2021 for the quarter that ended in Sep. 2021 was $-0.21. Hence, Kadmon Holdings's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Kadmon Holdings's Price-to-Tangible-Book or its related term are showing as below:
During the past 7 years, Kadmon Holdings's highest Price to Tangible Book Ratio was 63.77. The lowest was 0.00. And the median was 6.60.
A closely related ratio is called PB Ratio. As of today, Kadmon Holdings's share price is $9.50. Kadmon Holdings's Book Value per Sharefor the quarter that ended in Sep. 2021 was $-0.19. Hence, Kadmon Holdings's P/B Ratio of today is .
The historical data trend for Kadmon Holdings's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kadmon Holdings Annual Data | ||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | - | - | 5.52 | 6.05 | 10.48 |
Kadmon Holdings Quarterly Data | ||||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 7.15 | 10.48 | 63.77 | - | - |
For the Biotechnology subindustry, Kadmon Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kadmon Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Kadmon Holdings's Price-to-Tangible-Book falls into.
Kadmon Holdings's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2021 ) |
= | 9.50 | / | -0.206 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Kadmon Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Harlan Waksal | director, officer: President, CEO | WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042 |
Nancy Miller-rich | director | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001 |
Cynthia Schwalm | director | C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709 |
Arthur S Kirsch | director | 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4 |
David E Cohen | director | 3160 PORTER DRIVE, PALO ALTO CA 94304 |
Eugene Bauer | director | C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016 |
Tasos Konidaris | director | 103 JFK PARKWAY, SHORT HILLS NJ 07078 |
John L Ryan | officer: Executive Vice President, CMO | C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016 |
Steven Meehan | officer: EVP, Chief Financial Officer | 450 E. 29TH STREET NEW YORK NY 10016 |
Kyle Carver | officer: Principal Accounting Officer, Controller | 450 EAST 29TH STREET NEW YORK NY 10016 |
Gregory S. Moss | officer: EVP, General Counsel, Chief Compliance Officer | 450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | other: Former 10% owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Steven N. Gordon | officer: Exec VP, GC, Chief Admin, Comp | C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016 |
From GuruFocus
By Marketwired Marketwired • 06-02-2021
By Marketwired Marketwired • 10-04-2021
By PRNewswire PRNewswire • 09-09-2021
By Marketwired Marketwired • 09-09-2021
By Marketwired Marketwired • 09-09-2021
By ACCESSWIRE ACCESSWIRE • 07-16-2021
By PRNewswire PRNewswire • 06-02-2021
By ACCESSWIRE ACCESSWIRE • 08-20-2021
By Marketwired Marketwired • 05-28-2021
By PRNewswire PRNewswire • 09-10-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.